Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.09, while Vertex Pharmaceuticals Incorporated trades at $475.52 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | VRTX | |
|---|---|---|
52-Week High | $41.63 | $529.59 |
52-Week Low | $31.99 | $366.54 |
Market Cap | — | $120.89B |
Sector | — | Health |
Enterprise Value | — | $115.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
